PUBLISHER: IMARC | PRODUCT CODE: 1378759
PUBLISHER: IMARC | PRODUCT CODE: 1378759
The global enteric disease testing market size reached US$ 4.0 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 5.0 Billion by 2028, exhibiting a growth rate (CAGR) of 3.8% during 2022-2028.
Enteric diseases are caused by the entering of microorganisms, such as viruses, bacteria and parasites, in the body through the mouth. These pathogens can be acquired through contaminated food and water or by encountering feces of an animal or infected person. The common symptoms of enteric diseases are abdominal cramps, vomiting, nausea and anorexia that can lead to loss of fluids and essential nutrients from the body. In recent years, advancements in diagnostic technologies have revolutionized enteric disease testing and significantly increased the detection rates in symptomatic individuals.
The improper drainage and sanitation systems, unsafe drinking water and unhygienic living conditions can significantly increase the risk of enteric diseases. This, along with a substantial rise in medical tourism in recent years, represents one of the key factors impelling the market growth. Besides this, the increasing awareness among individuals about the benefits of early diagnosis is acting as another major growth-inducing factor. Apart from this, several international agencies, such as the World Health Organization (WHO) and the United Nations Children's Fund (UNICEF), are conducting awareness programs and setting up healthcare camps in different countries to promote the testing of enteric diseases. Moreover, several key players are focusing on the commercialization of novel testing technologies, which is contributing to the market growth. Furthermore, as human coronaviruses cases are associated with enteric diseases, several healthcare institutes are conducting studies to find interrelation between enteric disease and the coronavirus disease (COVID-19).
IMARC Group provides an analysis of the key trends in each sub-segment of the global enteric disease testing market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on product type, technique, disease type and end user.
Reagents and Consumables
Equipment
Molecular Diagnostics
Immunodiagnostics
Bacterial Enteric Disease
C. Difficile
Campylobacteriosis
Cholera
E. Coli
H. Pylori
Salmonellosis
Shigellosis
Viral Enteric Disease
Rotavirus
Norovirus
Others
Parasitic Enteric Disease
Amebiasis
Cryptosporidiosis
Giardiasis
Hospital Diagnostic Laboratories
Independent Diagnostic Laboratories
Academic and Research Institutes
Others
North America
United States
Canada
Asia Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
The report has also analysed the competitive landscape of the market with some of the key players being Abbott Laboratories, BD (Becton, Dickinson and Company), Bio-Rad Laboratories Inc., Biomerica Inc., Biomerieux SA, Cepheid Inc. (Danaher Corporation), Coris BioConcept, DiaSorin, Meridian Bioscience Inc. and Quest Diagnostics.